Fig. 1: Sample collection and cohort overview.

a Schematic of sample collection and sequencing summary for participants with a post-treatment sample collected within 7 months of treatment completion. b Clinical characteristics of NAT participants. c Clinical characteristics of ADJ participants. d Participant-specific concordance between somatic variants identified in FFPE tumour and plasma samples for participants with a detectable panel-targeted mutation.